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change directed at disease-specific bundling strategies. This study was per-
formed to evaluate rates and predictors of 30-day readmission from a
multicenter trial data set.
Methods: We analyzed the PREVENT III data set of 1404 CLI
patients undergoing LEB at 83 North American centers. The primary end
point was readmission 30 days of discharge. Secondary end points in-
cluded graft patency and limb salvage evaluated in the context of readmis-
sion.
Results: We analyzed 1356 patients, of these, 23 (1.7%) died in-
hospital and were excluded from re-admission analyses. Overall, 327 of 1333
patients (24.5%) were readmitted 30 days of discharge. Reasons for
readmission included 127 (39%) wound infections in the index leg, 75 (23%)
nonvascular reasons, 68 (20.9%) additional procedures in the index leg, and
19 graft failures (5.8%). Univariate predictors are shown in the Table.
Adjusted independent predictors of 30-day readmission included wound
infection (odds ratio [OR], 4.1; 95% confidence interval [CI], 3.0-5.4; P
.0001), renal failure (OR, 4.1; 95% CI, 1.9-8.8; P  .0004), early lost
patency (OR, 1.9; 95% CI, 1.2-2.9; P  .003), dialysis (OR, 1.8; 95% CI,
1.2-2.6; P .003), and female gender (OR, 1.3; 95% CI, 1.0-1.8; P .03).
Patients readmitted 30 days had lower rates of limb salvage at 1 year
(78%  2.4% vs 91%  0.9%, P  .0001). Thirty-day readmission was
predictive of limb loss (HR, 2.25; 95% CI, 1.6-3.1; P  .0001) at 1 year,
after adjustment for other factors.
Conclusions: Readmission after LEB for CLI is common (24%) and
associated with defined clinical predictors. Readmission is associated with
long-term limb loss. These data provide benchmark values for this complex
patient population and may prove useful as disease-specific bundling strate-
gies are derived.





Pre-op factors, No. (%)
Female gender 333 (33.1) 142 (43.4) .0008
Dialysis dependence 109 (10.9) 52 (15.9) .02
Tissue loss indication 733 (72.9) 255 (78.0) .05
Post-op factors
Length of stay, mean
[SD] days
8.4 [8.9] 9.7 [9.1] .0009
Wound infection,
No. (%)
140 (13.9) 133 (40.7) .0001
Acute renal failure,
No. (%)
15 (1.5) 17 (5.2) .0005
Early graft-related
event, No. (%)
76 (7.5) 44 (13.5) .002
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Introduction and objectives: This study reports the 2-year diameter
and volume data for abdominal aortic aneurysms (AAAs) treated in the U.S.
pivotal clinical trial of the Endurant Stent Graft System.
Methods: From April 2008 to May 2009, 150 patients were treated
with the Endurant stent graft as part of a prospective multicenter trial. The
main inclusion criteria were AAA diameter 5 cm, neck length 10 mm,
and neck angulation 60°. A core laboratory reviewed all imaging. Expan-
sion was defined as 5 mm diameter or 5% by 3-dimenional volume.
Results: Stent graft implant was successful in 149 of 150 patients. The
6-month volume results were nearly identical to the 24-month diameter
results, and all AAAs identified with expansion by diameter at 24 months had
expansion by volume criteria (but not diameter) at 6 and 12 months.
Change in AAA size was more likely to be identified by volume at all time
points, with13% of AAAs classified as “no change” by volume criteria at 1
and 2 years (P  .05). Most AAAs classified as “no change” by diameter
criteria were shrinking by volume criteria. Secondary intervention for en-
doleak occurred in five patients, all suspected type II endoleak. All were
identified as expanding earlier by volume, including two ultimately identi-
fied to be a type I endoleak. There were no ruptures or aneurysm-related
deaths.
Conclusions: Midterm results of the Endurant pivotal trial are good,
with low expansion rates at 2 years, even by volume criteria. Three-
dimensional volume detects aneurysm shrinkage and expansion on average
18 months sooner than diameter, allowing for earlier reassurance in most
patients and earlier intervention in the small minority who need it.
Table. AAA outcomes over time
Outcome Decrease (%) No change (%) Increase (%)
Diameter
6 mon 31 69 0
12 mon 47 53 0
24 mon 63 35 2
Volume
6 mon 63 34 4
12 mon 79 13 7
24 mon 78 12 10
The Effect of Chronic Oral Anticoagulation on the Durability and
Success of Endovascular Aortic Aneurysm Repair (EVAR)
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Introduction and objectives: It has been suggested that long-term
use of warfarin can affect the durability of endovascular aneurysm repair
(EVAR) by continued sac expansion, possible rupture, and the need for
further surgical interventions. The purpose of this study was to determine
whether chronic anticoagulation therapy with warfarin is associated with an
increased risk of rupture or need for reintervention after EVAR.
Methods: We reviewed the records of 401 consecutive patients who
underwent EVAR at a single institution from 2003 until 2011. Patients on
warfarin were compared with a control group not anticoagulated. Primary
end points were rupture, explant, reintervention, death, and a composite
outcome if any of these occurred. The presence of an endoleak at last
follow-up and change in aneurysm sac size of 5 mm were secondary end
points. Cox proportional hazards models were used to estimate the effect of
warfarin use on the primary and secondary outcomes, controlling for age,
sex, obesity, specific comorbidities, antiplatelet drugs, statin use, and ur-
gency of EVAR.
Results:Of 401 patients, 363 (90.5 %) with a median follow-up period
of 29 months had sufficient data for analysis. Warfarin use was not associated
with an increased risk of any of the primary or secondary end points (Table).
After controlling for covariates and length of observation via Cox propor-
tional hazards models, we found the effect of warfarin remained insignifi-
cant. There was an increased in endoleak rate and adverse outcomes after
emergency EVAR and in those patients deemed unfit for open surgical
repair.
Conclusions: Chronic oral anticoagulation with warfarin does not
appear to affect the incidence of endoleak after EVAR or the need for




Death, Explant, Reintervention, Any of these,
No. (%) No. (%) No. (%) No. (%)
Warfarin 68 7 (10) 3 (4) 6 (9) 16 (24)
No warfarin 295 35 (12) 5 (2) 25 (8.5) 65 (22)
P NS NS NS NS
Atrio-Femoral BypassWithMotor-Evoked Potential Monitoring Low-
ers the Rate of Death and Paraplegia After Complex Thoracoabdomi-
nal Aortic Aneurysm Repair
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Introduction and objectives: We recently reported improved early
mortality and paraplegia rates in a small cohort of patients with type I-III
thoracoabdominal aortic aneurysms (TAA) treated with atrio-femoral by-
pass (AFB) and motor-evoked potentials (MEVP) when compared with a
propensity-matched cohort of patients treated with the clamp-and-sew
method (CS). The use of AFB/MEVP increases the level of complexity of
TAA repair, and it is unclear if the early benefits will be sustained when this
is applied to a general population with type I-III TAA, which is the goal of
this study.
Methods: Consecutive patients undergoing repair of nonruptured
Crawford extent I-III TAA from January 1987 to December 2011 were
identified. Patients were stratified according to operative approach (AFB/
MEVP vs CS). End points included long-term survival and the composite
outcome of perioperative death and paraplegia. A multivariate, risk-adjusted
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model was then created to determine if the operative approach indepen-
dently influenced outcome.
Results: There were 485 patients (385 CS [79%]; 100 AFB/MEVP
[21%]). The cohorts iffered in that the AFB/MEVP group was younger
(65.8  12.5 vs 70.9  9.7 years; P  .001), had more extent I/II
aneurysms (66% vs 0.1%; P  .0005), and had more chronic dissections
(30.3% vs 18.9%; P  .0018). Operative variables differed in that the
AFB/MEVP cohort had longer operative times (434  112 vs 324  98
minutes; P  .001) and higher blood turnover (6028  3473 vs 3581 
3111 mL; P .0001). There was no difference in AFB/MEPB vs CS for the
rate of intraoperative death (1.0% vs 0.05%; P  .050), length of intensive
care unit stay (9.6  8.6 vs 9.5  12.3 days CS; P  .095), and hospital
length of stay (19.9 12.6 vs 21.6 23.5 days; P .049). The composite
perioperative death and paraplegia rate was lower in the AFB/MEVP cohort
(7% vs 19%; P  .0004). The multivariate model for predictors of the
composite outcome showed that AFB/MEVP was protective (odds ratio,
0.039 [0.17, 0.9]; P  .0028). Long-term (4-year) survival was also
improved in the AFB/MEVP group (73%  6% vs 60%  3%; P  .0004).
Conclusions: AFB/MEVP is an independent predictor of reduced
perioperative death and paraplegia as well as improved long-term survival in
patients undergoing repair of type I-III TAA and is the preferred operative
strategy over CS.
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Introduction and objectives: The U.S. Food and Drug Administra-
tion has approved devices for endovascular management of thoracic aortic
degenerative pathology (TEVAR); however, few data exist describing the
outcome of TEVAR for aneurysms due to chronic type B aortic dissection
(An-cTBAD). This study was undertaken to define the results of endovas-
cular treatment of An-cTBAD.
Methods: A retrospective analysis of all patients treated for An-cTBAD
was performed. Patient demographics, procedural outcomes, and anatomic
covariates were aggregated. Reintervention and mortality were estimated
using life-tables.
Results: Eighty patients (69 men [87%]) underwent TEVAR to treat
An-cTBAD with mean  standard deviation age 58  13 years and median
follow-up of 28 months (range 1-74 months). Median time from diagnosis
of TBAD to TEVAR was 27 months (range, 1-74 months). Prior aortic
root/arch replacement had occurred in 29% (n 23) at a median interval of
28.5 months (range, 0.5-312 months). Mean aneurysm diameter was 62.0 
9.9 mm. Coverage occurred proximal to zone 3 in 75% (n  60) of
patients, and 24% (n  19) underwent a carotid-subclavian bypass or arch
debranching procedure. Spinal drains were used in 81% (preoperatively in
73% [n 59]; and postoperatively in 8% [n 6]). Length of stay was 6.5
4.7 days, with a composite morbidity of 26% and in-hospital mortality of
2.5% (n  2). Spinal cord ischemia developed in 9% (n  7), with a
permanent deficit observed in 6.2% (n 5). Aneurysm diameter reduced or
stabilized in 65%. The false lumen thrombosed completely within the
thoracic aorta in 52%, and reintervention within the treated aortic segment
was required in 16% (n  13). At 1 year, freedom from reintervention was
75% and mortality was 83%.
Conclusions:TEVAR for An-cTBAD can be performed safely, but spinal
cord ischemia rates may be higher than previously reported. Reintervention
rates are acceptable; however, lack of uniform aneurysm diameter reduction and
false lumen thrombosis underscore the need for longer-term follow-up and
greater patient numbers to determine procedural durability and efficacy.
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Introduction and objectives: To review the natural history of blunt
thoracic aortic trauma (BTAT) over a 14-year period at our level 1 trauma
center and to compare open vs endovascular treatment.
Methods: All patients with BTAT presenting to a level 1 trauma center
from 1998 to 2011 were included in a retrospective analysis. Multiple data
points and short-term and moderate-term outcomes were ascertained by record
review.
Results: The review identified 129 patients with BTAT. Of these, 32
(25%) were dead on arrival, 38 (29%) underwent an emergency department
thoracotomy and died, 33 (25.5%) underwent open repair, 14 (11%) under-
went endovascular repair, nine (7%) underwent a combination of proce-
dures, and three (2%) were managed nonoperatively. Demographics, includ-
ing injury severity score (average, 36) and revised trauma score (average, 9),
were similar between the open and endovascular groups. The location of
injury was also similar between groups (89% of injuries occurring at or 2
cm of the left subclavian artery). Rates of stroke, myocardial infarction, renal
failure, and paralysis, length of stay (LOS), and 30-day mortality were
decreased in the endovascular repair group compared with the open repair
group (Table). Intraoperative time (P  .053), need for intraoperative red
blood cell transfusion (P .001), and estimated blood loss (P.001) were
all decreased in the endovascular group vs the open group. The average LOS
for patients treated with endovascular repair was 15 vs 24 days in those
treated with open repair (P  .003).
Conclusions: The incidence of BTAT is low but associated mortality is
significant. During the 14-year period, there was a clear change in manage-
ment preference from open repair to endovascular repair. Outcomes includ-
ing stroke, myocardial infarction, renal failure, paralysis, LOS, and death
seem to be reduced in the endovascular group.
Table. Comparison of complications between the open and endovascular
repair groups
Complications 30 days
Repair group, No. (%)
POpen Endovascular
Death 14 (42) 1 (7) .012
Myocardial infarction 2 (6) 0 .257
Stroke 3 (9) 1 (7) .257
Renal failure requiring
HD
3 (9) 0 .143
Paralysis 2 (6) 0 .473
Stent collapse . . . 1 (7) . . .
Thrombospondin-1 Differentially Regulates MicroRNAs in Vascular
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Introduction and objectives: Thrombospondin-1 (TSP-1) is an im-
portant regulator of vascular smooth muscle cell (VSMC) physiology and
gene expression. MicroRNAs (miRNA), which have emerged as potent
regulators of cell function, are small molecules that regulate protein trans-
lation. miRNAs are be involved in intimal hyperplasia and atherosclerosis
and are upregulated in the vasculature in diabetes. The purpose of this study
was to identify miRNAs regulated by TSP-1 in VSMCs.
Methods: Human VSMCs were used. Both treatment groups con-
sisted of three separate experiments, and the miRNA microarray was per-
formed in triplicate for each sample. Cells were treated for 6 hours with basal
media or TSP-1, both supplemented with 0.2% fetal bovine serum. Cells
were snap frozen and RNA was extracted. An Affymetrix GeneChip miRNA
array analysis was performed. Data was analyzed by analysis of variance with
significance set at P  .05.
Results: TSP-1 upregulated 11 miRNAs and downregulated 23 miR-
NAs in VSMCs (P  .05). The most upregulated miRNA was miR-224
(1.57-fold). Also increased were miR-224 and miR-200c. The miRNA most
downregulated by TSP-1 was miR-17*, which was decreased by 2.25-fold.
Interestingly, 14 of the miRNAs altered were of the miRNA* strand.
Conclusions:The present study examined the effect of TSP-1 on miRNA
expression in VSMCs. miRNAs regulate protein expression at the level of
translation and may represent a significant mechanism by which TSP-1 regulates
VSMC function. In addition, several of the miRNAs identified, such as miR-224
and miR-200c, have a role in vascular function. The miR-17 family, which
exhibited reduced expression in this study, is known to inhibit cell proliferation
and migration. We further found that several miRNA* strands were altered. The
miRNA* strand, once thought to be the inactive complimentary strand of the
mature miRNA, is now appreciated to regulate cellular function and may
represent new targets for modifying TSP-1 signaling.
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Introduction and objectives: Previous work has demonstrated that
poly (ADP-ribose) polymerase (PARP) inhibition confers protection on
skeletal muscle ischemia–reperfusion (IR) injury in diabetic mice. Published
reports, including a model of renal IR injury in normal nondiabetic mice,
have shown that poly (ADP-ribosylation) of the critical glycolytic enzyme
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